Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(12): e51562.
Published online 2012 December 18. doi:  10.1371/journal.pone.0051562
PMCID: PMC3525594

Prophylactic Valproic Acid Treatment Prevents Schizophrenia-Related Behaviour in Disc1-L100P Mutant Mice

Gianluigi Forloni, Editor



Schizophrenia is a neurodevelopmental disorder with onset early in adulthood. Disrupted-In-Schizophrenia-1 (DISC1) is a susceptibility gene for schizophrenia and other psychiatric disorders. Disc1-L100P mutant mice show behaviors relevant to schizophrenia at 12 weeks, but not at 8 weeks of age, and may be useful for investigating the onset of schizophrenia in early adulthood.


We investigated whether early valproic acid treatment would prevent behavioral, cellular and gene expression abnormalities in Disc1-L100P mutants.


Valproic acid prevented hyperactivity and deficits in prepulse inhibition and latent inhibition in Disc1-L100P mice. Genome-wide transcription profiling identified Lcn2 (lipocalin2) transcripts as being elevated by the Disc1 mutation and corrected by valproate. Disc1-L100P mice also had increased glial cell numbers in the subventricular zone, which was normalized by valproate. Genetic deletion of Lcn2 normalized glial cell numbers and behavior in Disc1-L100P mutants.


Pharmacological treatments are a feasible way of preventing abnormal behaviour in a genetic model of schizophrenia. Lcn2 is a potential novel drug target for early intervention in schizophrenia.


Schizophrenia is a neurodevelopmental disorder in which genetic and environmental factors disturb brain development, but the symptoms typically do not emerge until early adulthood [1]. Disrupted-In-Schizophrenia-1(DISC1) is a risk gene for schizophrenia and other mental illnesses, [2] encoding a scaffold protein [3] that is critical for adult neurogenesis [4], [5], neuronal migration, dendrite maturation and synaptogenesis [6], [7]. Better understanding of the molecular mechanisms by which DISC1 variation alters neurodevelopment could lead to new treatment targets for neuropsychiatric illness.

There are a number of mouse models with DISC1 mutations or altered DISC1 expression [2], demonstrating that the neurobiological and behavioral effects of DISC1 perturbation are time dependent [8], [9]. For example, transient expression of the DISC1 C-terminus on postnatal day 7 had effects not seen when expression was induced in adulthood [8]. The timing of expression of truncated DISC1 also has distinct behavioral effects [9]. Although behavioral impairments in various mutant DISC1 mouse models have been observed in adult mice [10], the behavior of these mice as young adults has not yet been investigated.

We previously characterized Disc1-L100P mice generated by ENU mutagenesis [11]. Disc1-L100P mutants have disrupted pre-pulse inhibition (PPI), latent inhibition (LI), and working memory, in addition to hyperactivity. These schizophrenia endophenotypes [12], were corrected by antipsychotic treatment [11], [13]. Disc1-L100P mice are more sensitive to amphetamine, and have more D2 receptors in the striatum [13]. The Disc1-L100P mutation also reduced interactions between DISC1 and phosphodiesterase 4B (PDE4B) [11], and with glycogen synthase kinase-3 (GSK-3) [14]. Both rolipram (a PDE4B inhibitor) and TDZD-8 (a GSK-3 inhibitor) normalized behavior in Disc1-L100P mutants [11], [14]. Furthermore, the Disc1-L100P mutation impaired cortical development and cellular architecture [7], and affects expression of synaptic modulators neurexin 1 and 3 (Nrxn1/3) at critical developmental periods [15].

Because the Disc1-L100P mouse has many features consistent with schizophrenia, we sought to determine whether there was also an early adult onset of behavioral abnormalities. We found the behavior of 8 week-old mice to be normal [11], [13], [14], so we hypothesized that early intervention could rectify neurodevelopment and prevent abnormal behaviors emerging later in adulthood (12 weeks of age). Valproic acid (2-propylpentanoic acid) [16], given to Disc1-L100P mutant mice in early adulthood, prevented the emergence of schizophrenia-related behaviors later on. We profiled gene transcription in brain and identified higher Lcn2 (Lipocalin2) transcript levels in Disc1-L100P mice that were normalized by valproic acid. Lcn2 is co-expressed with glial fibrillary acidic protein (GFAP) in brain, and the increased number of glial cells in Disc1-L100P mutants was corrected by valproic acid. Genetic ablation of Lcn2 [17] normalized both behavior and glial cell numbers in Disc1-L100P mutants. Our work demonstrates that pharmacological intervention can prevent the onset of schizophrenia-related behaviors and suggests Lcn2 as a novel drug target for preventive treatment of schizophrenia.

Materials and Methods

Ethics Statement

All animal procedures were approved by the Toronto Centre for Phenogenomics (TCP) Animal Care Committee (AUP number 12-0025a-H) and followed the requirements of the Province of Ontario Animals for Research Act and the Canadian Council on Animal Care.


Disc1-L100P homozygous mutants were generated as previously described [11], and backcrossed with C57BL/6 mice for 10–14 generations. Experiments were performed with 8, 12 and 15 week-old animals in sex-balanced groups. Lcn2-KO mice were backcrossed with C57BL/6J for 10 generations [18] and bred with Disc1-L100P homozygous mice to obtain WT, heterozygous and homozygous Disc1-L100P mice having two, one or no copies of Lcn2. Groups of 3–5 same-sex littermates were housed in filtered polycarbonate cages at 21±1°C, lights on 0700 h-1900 h and humidity at 50–60%. Animals were fed sterile Purina mouse chow and water ad libitum, except in the latent inhibition experiments. Behavioral experiments were conducted blind to genotype and drug treatment.

Behavioral Assays

Locomotor activity

Monitored for 30 minutes in a directly illuminated (600 Lux) clear Perspex chamber (42 cm×42 cm×30 cm; Accuscan Instruments Inc, Ohio, USA) by interruptions of 16 horizontal and 16 vertical infrared beam sensors 2.5 cm apart.

Pre-pulse Inhibition (PPI) of Acoustic Startle Response (ASR)

Measured as previously described [11]. Five types of trials were used: (i) Pulse alone - single white noise burst (120 dB 40 ms); (ii) Prepulse+pulse (PP69P, PP73P, PP81P) – noise prepulse (20 ms at 69, 73, or 81 dB) followed by startle pulse (120 dB 40 ms) 100 ms after the prepulse onset; (iii) No-stimulus - background noise only (65 dB). Sessions were structured as follows: (i) 15-minute acclimation at background noise level; (ii) five Pulse trials; (iii) ten blocks each containing all five trials (Pulse, PP69P, PP73P, PP81P, No-stimulus) in pseudorandom order; (iv) five Pulse trials. The force intensity for each trial was recorded as the startle level. The percentage PPI induced by each prepulse intensity was calculated as [1-(startle amplitude on prepulse trial)/(startle amplitude on pulse alone)]*100%.

Latent Inhibition (LI)

Assessed as previously described [11]. Mice were trained to drink in the experimental chamber for 5 days, 15 minutes per day. The LI procedure consisted of Pre-exposure, Conditioning, Lick Retraining and Test sessions. Pre-exposure: The pre-exposed (PE) mice received 40 white noise presentations (60 s inter-stimulus interval). The non-pre-exposed (NPE) mice were confined to the chamber for the same time without receiving the stimuli. Conditioning: All mice received fear conditioning to the noise stimulus. Two noise-shock pairings were used (10 s 85 dB white noise; 1 s 0.37 mA shock). Test: The noise was activated between licks 75–101. The following times were recorded: time to first lick, time to complete licks 50–75 (before noise onset: A period) and time to complete licks 76–101 (after noise onset: B period). The suppression ratio was calculated as A/(A+B).

Drug Administration Schedule

Valproic acid sodium salt (Sigma-Aldrich, Canada) in 0.9% NaCl was injected intraperitoneally (i.p) at 200 mg/kg, twice daily for 14 days [19]. Behavioral testing started 20 hours after the last injection (LI sessions were between injections), using independent cohorts for each test and for microarrays, Western blotting, and immunohistochemistry. Mice for tissue analysis were killed 20 hours after the last valproate injection, either by cervical dislocation, or anaesthetized with pentobarbital.

Preparation of Total RNA

Gross brain dissections were performed to obtain brain stem (BS), frontal cortex (FC), hippocampus (HIP), and striatum (STR) samples, from which total RNA was extracted as described previously [20]. Samples were mechanically homogenized and lysed using Trizol® Reagent (Invitrogen, Carlsbad, CA). RNA was precipitated with 70% ethanol, and purified and treated with DNAase using the Absolutely RNA Miniprep® kit (Stratagene, La Jolla, CA).

Target Preparation and Microarray Hybridization

Microarray hybridization and scanning were done at the Génome Québec Innovation Centre (Montreal, QC). RNA samples were quantified using the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and evaluated using the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Complementary RNA (cRNA) was amplified and biotinylated using the Illumina TotalPrep Amplification Kit for 3–6 replicates within each treatment-genotype combination and hybridized to MouseRef-8 v2.0 Expression BeadChips (>25,000 probes; Illumina, San Diego, CA). BeadScan software (version 3, 2006) was used to identify bead positions and to extract raw data.

Microarray Analysis

Each brain region was analyzed independently and identically. A two-factor, two-level design was used, with the factors being drug treatment and genotype. Raw array data were loaded into the beadarray package (v1.10.0) of BioConductor [21]. Following BASH analysis to remove spatial artifacts [22], data were pre-processed using Edwards background correction [23] and normalized using variance-stabilization (vsn package of BioConductor v3.8.0) [24]. A two-level, two-factor general linear model was then fit to the pre-processed expression values from each bead type using the limma package (v2.16.3) of BioConductor, followed by an empirical Bayes moderation of the standard error and a false-discovery rate (FDR) adjustment for multiple-testing. Genes were selected at a 10% FDR threshold in any contrast. Both normalized and pre-processed array data are available in GEO (GSE17735). Data were visualized using unsupervised machine-learning [25]. The mean normalized signal intensities for each (tissue, genotype, treatment) tuple were collated into a single matrix, with rows as genes and columns as conditions. Rows were selected based on sequential variance (0.1, 0.25, 0.5, 1.0) or signal intensity (7,8,9,10,11,12) thresholds. This matrix was mean-centered and root-mean-square-scaled, and then subjected to agglomerative hierarchical clustering using complete linkage with Pearson’s correlation as a distance metric. Heatmaps were generated in the R statistical environment (v2.8.1) using the lattice (v0.17–20) and lattice Extra (v0.5-4) packages. Functional analysis was performed using the NIAID’s DAVID resource (v2008).

Verification of Microarray by Quantitative RT-PCR

The mRNA levels of Adar, Egr2, Slc40a1, Mrpl39, Slc6a12, Lcn2, Arc, Dusp1, Purb, Cyr61, Igf1 and eiF4ebp2 were measured using quantitative RT-PCR (qRT-PCR). cDNA was prepared using the Omniscript Reverse Transcription kit (Qiagen, Valencia, CA), and qRT-PCR was performed in quadruplicate using a reaction volume of 50 µL on the ABI PRISM 7500 (Applied Biosystems Inc., Foster City, CA). The qRT-PCR cycle consisted of activation of AmpErase UNG (50°C, 2 min), Taq activation (95°C, 10 min), 40 cycles of denaturation (95°C, 15 sec), and elongation (60°C, 1 min) during which fluorescence was measured. Gene expression was quantified using Gapdh and β-actin as endogenous controls for normalization. All assays were from ABI. Correlation between microarray data (fold-change in log 2-space) and qRT-PCR data (fold-change in log 2-space, normalized to Gapdh and β-actin; expressed as relative normalized expression, RNE, values) was analyzed in R (v2.9.1).

Western Blotting

Tissues were homogenized in RIPA buffer (Sigma-Aldrich). After centrifugation at 10,000 g at 4°C for 20 min, the supernatant was extracted and protein concentrations were measured by Bradford assay. Aliquots of protein extract (20–40 µg) were boiled with Laemmli sample buffer, separated by 10–15% SDS-PAGE, and transferred to PVDF membranes (Life Sciences). Blots were immunostained overnight at 4°C with antibodies from Santa Cruz Biotechnology: rat anti-LCN2 monoclonal (1:1000), rabbit anti-Dusp1 polyclonal (1:1000), goat anti-Cyr61 polyclonal (1:1000), and rabbit β-actin polyclonal (1:2000). Immune complexes were detected using appropriate peroxidase-conjugated secondary antibodies and a chemiluminescent reagent (ThermoScientific).


After pentobarbital anesthesia (120 mg/kg), mice were perfused transcardially with 4% periodate-lysine-paraformaldehyde at 4°C. Paraffin-embedded brain was cut into 5 mm thick sagittal sections, de-paraffined with xylene and rehydrated with ethanol. After blocking with Dako, the sections were incubated with primary antibodies overnight (rabbit anti-ki67, Lab Vision, 1:200), anti-neuronal nuclear protein (anti-NeuN, Chemicon, 1:200), or anti-glial fibrillary acidic protein (anti-GFAP, COVANCE, 1:200), followed by incubation with secondary antibody (goat anti-rabbit IgG, Vector Labs, 1:200) and tertiary antibody (ABC, Vector labs, 1:50). DAB color development was followed by scanning (Aperio Scanner). Apoptosis was assessed by TUNEL assay (Roche Applied Science) following the manufacturer’s protocol. Cells were counted using Aperio ImageScope software. At least four animals per condition (genotype, drug) were used, and a total of four sections per animal were analyzed.

Confocal Microscopy

After pentobarbital anesthesia and perfusion as above, whole brain was immersed in 4% PFA for 24 hours, and 100 µm sagittal slices were cut on a vibratome. Next, slices were immersed in 4% BSA, 0.1% Triton-X 100, PBS solution for 15 minutes. Primary antibodies (rabbit anti-LCN2 polyclonal, Santa Cruz Biotechnology, 1:100) and mouse anti-GFAP (1:250) were incubated with free-floating slices for 48 hours at 4°C. Slices were washed 3×10 minutes in blocking-permeabilizing solution and incubated with secondary antibodies (rabbit LCN2-CY5, 1:200 or mouse GFAP-CY2, 1:200) for 2 hours at 20°C. Following incubation, slices were washed again (3×10 minutes) and mounted on glass slides. For quantitative studies 3–5 mice per genotype and 4 slices per mouse were examined (Zeiss LSM 510 confocal microscope). All images were acquired with fixed exposure settings and analysed using Nikon EZ-C1 FreeViewer v3.9.

Statistical Analysis

The effects of the Disc1-L100P mutation, age, valproate treatment and Lcn2 deletion on mouse behaviors, cell counts, and mRNA or protein levels were evaluated by ANOVA or unpaired t-test. Because there were no significant sex effects, data for both sexes were combined. Significant main effects or interactions were followed by the Fisher’s least significance difference (LSD) post-hoc test with significance set at p<0.05.


Disc1-L100P Mice Behave Abnormally at 12 but not at 8 Weeks of Age

We assessed behavior of Disc1-L100P mutants at 8 weeks of age, when PPI and LI normally develops [26], [27], [28], and later in adulthood (12 weeks of age). We focused on behaviors relevant to schizophrenia: hyperactivity, PPI, and LI [29]. Disc1-L100P mutants were hyperactive at 12 but not 8 weeks of age compared to WT mice (Figure 1a). A mild PPI deficit in 8 week-old Disc1-L100P mice became more pronounced at 12 weeks (Figure 1b). Disc1-L100P mice had normal Acoustic Startle Response (ASR) at 8 weeks of age, which decreased significantly by 12 weeks of age (Figure 1c). Similarly, young adult Disc1-L100P mutant mice showed LI, but had disrupted LI at 12 weeks of age, whereas WT mice showed robust LI at both ages (Figure 1d).

Figure 1
Disc1-L100P mutant mice show schizophrenia-related behavior at 12 but not 8 weeks of age.

Valproic Acid Prevented Schizophrenia-related Behavior in Disc1-L100P Mice

Valproic acid treatment between 10 and 12 weeks of age prevented hyperactivity, PPI deficits and ameliorated ASR, but did not immediately correct LI deficits in Disc1-L100P mice (Figure 2a–c and Table S1). All behaviours in valproic acid-treated Disc1-L100P mice were comparable with WT mice, three weeks after the last dose of valproic acid (Figure 2d–f). LI actually improved in the three weeks after valproic acid treatment stopped. These data show that valproic acid treatment had lasting effects on behavior, even after the medication had been discontinued.

Figure 2
Chronic treatment with valproic acid between 10 and 12 weeks of age prevented the emergence of hyperactivity and PPI deficits in Disc1-L100P mutants and had a delayed effect on LI.

Transcriptomic Analysis

The Disc1-L100P mutation had the most pronounced effect on gene expression in the hippocampus (61 genes), with 13 genes showing altered expression in brain stem, but no changes in gene expression in striatum or frontal cortex (Table 1 and Figure 3a). Functional annotation of genes in the hippocampus revealed that most are involved in cell proliferation (23%) and cytoskeleton/cell shape (15%). Valproic acid significantly altered expression of 3 genes in hippocampus (Hist1h1c, Hist1h2be and Clcn2) and 2 genes in striatum (Egr2 and Fosb). Among 61 genes altered by the Disc1-L100P mutation, valproate corrected the expression of 13 genes (21.3%) in hippocampus and Lcn2 in the brain stem. Expression of 14 genes was changed only in valproate-treated Disc1-L100P mutants. The specific genes are listed in Tables S2-S6.

Figure 3
Gene expression changes induced by the Disc1-L100P mutation and by treatment with valproic acid.
Table 1
The number of unique Illumina beads identified as differentially expressed in each of the three conditions and four brain regions.

Verification of Gene Expression by qRT-PCR

We used qRT-PCR to validate mRNA levels of genes for which: (1) the effect of Disc1-L100P mutation was accompanied by the opposite effect of valproic acid (genotype × drug interaction) on gene expression (Arc, Purb, Egr2, Dusp1, Slc40a1, Mrpl39, and Igf1), (2) Disc1-L100P mutation alone had a significant effect on expression (Slc6a12, Adar, Lcn2 and EiF4ebp2), and (3) genotype × drug interaction had a significant effect on expression (Cyr61). Correlation analysis of microarray and qRT-PCR data validated 7/12 genes (Egr2, Slc40a1, Arc, Dusp1, Cyr61, Lcn2 and Slc6a12). We obtained an overall validation rate of 0.6 (Figure 3b; p = 0.037). The strongest candidate transcript was Lcn2 (Figure 3c), and Lcn2 protein levels were consistent with qRT-PCR (Figure 3d–e). In particular, there was more Lcn2 brainstem mRNA in Disc1-L100P mutants (p<0.05) that was normalized by valproic acid.

Valproic Acid Corrected Increased Cell Proliferation in Disc1-L100P Mutants

Given that DISC1 [4], [5], [6] and LCN2 [30] are both involved in cell proliferation and that cell proliferation was the largest functional category of altered transcripts (23%), we performed immunohistochemistry on the cell proliferation marker Ki67 in vehicle/valproic acid-treated Disc1-L100P and WT mice. As shown in Figure 4a–b, vehicle-treated Disc1-L100P mutants had more Ki67+ cells in olfactory bulbs (OB), rostral migratory stream (RMS), and subventricular zone (SVZ), but not sub-granular zone (SGZ) of hippocampus. These are the main areas for adult neurogenesis [31]. Valproic acid no effect on Ki67+ cell counts in WT mice.

Figure 4
Increased GFAP+ cell proliferation in Disc1-L100P mutants normalized by valproic acid.

Disc1-L100P Mutation Increased Glia but not Neurons in SVZ

To identify the proliferating cells in Disc1-L100P mutants, we performed immunohistochemistry with antibodies against neuronal nuclear protein (NeuN) and glial fibrillary acidic protein (GFAP). As shown in Figure 2c–d, there was a significant increase in GFAP-positive cells in OB, RMS and SVZ in Disc1-L100P mutants compared to WT mice but not in the hippocampus. Most post-mortem studies in schizophrenia report no or minimal gliosis [32], but some find gliosis in periventricular structures [33]. There was no difference in the number of NeuN-positive cells in all brain areas examined between the genotypes. We performed TUNEL staining to assess cell death and found no differences between Disc1-L100P and WT littermates. We also assessed cell proliferation in young animals and did not find significant differences between genotypes in the brain regions studied (Table S7).

Genetic Deletion of Lcn2 Corrected Excess GFAP+ Cells and Normalized Behavior in Disc1-L100P Mutant Mice

We sought to assess the role of Lcn2 in mediating excess glial cells and schizophrenia-related behavior by crossing mice that lack both alleles of Lcn2 to either WT mice or Disc1-L100P mutants [11], [17]. LCN2 is an autocrine mediator of reactive astrocytosis [34], which could be related to glial proliferation. Immunostaining with LCN2 and GFAP antibodies revealed their co-expression in OB, RMS, SVZ, cortex, hippocampus, and brain stem (Figure 5a). The expression levels of the two genes were positively correlated (r = 0.53, p<0.01) (Figure 5b). Disc1-L100P mutation increased LCN2 and GFAP proteins in the SVZ (Figure 5c–d) as well as in OB, RMS but not in the subgranular zone (SGZ). Genetic inactivation of Lcn2 reduced the excess GFAP+ cells in SVZ (Figure 5c–d), OB and RMS with no effect in SGZ in Disc1-L100P mutant mice (Table S8). Finally, we assessed effect of genetic inactivation of Lcn2 on schizophrenia-related behaviors. Ablation of both copies of Lcn2 normalized locomotion, PPI, LI and ASR abnormalities of Disc1-L100P mutants to the level of WT control mice (Figure 5e–g).

Figure 5
LCN2 is co-expressed with GFAP in the brain and levels are associated with behavior in Disc1-L100P mice.


Our results show that: (1) abnormal behaviors in Disc1-L100P mutant mice are present at 12 weeks but not 8 weeks of age; (2) treatment with valproic acid prevented the emergence of abnormal behaviors in Disc1-L100P mutants; (3) 23% of transcripts altered in Disc1-L100P mice are implicated in cell proliferation, including Lcn2; (4) there were more glial cells in the SVZ, RMS and OB but not in SGZ of Disc1-L100P, which was corrected by valproic acid; (5) genetic inactivation of Lcn2 corrected excess glial cells and schizophrenia-related behavior in Disc1-L100P mutants (Figure 6). We have identified a novel function for Lcn2 as a regulator of glial proliferation in the SVZ and of behaviors relevant to schizophrenia.

Figure 6
Summary of results.

An important question about the pathophysiology of schizophrenia is why the psychotic symptoms emerge in the third decade of life, despite high heritability and the presence of premorbid abnormalities in early childhood [35]. Longitudinal magnetic resonance imaging (MRI) studies reveal progressive structural brain changes prior to the first episode of psychosis [36]. However, it remains unknown whether these premorbid structural abnormalities can be prevented by prophylactic early intervention. Many schizophrenia patients have a prodromal period [1], [37] of social and functional decline [38], that provides an opportunity for early intervention.

pWe have chosen to investigate the potential for valproic acid to prevent the emergence of behavioral abnormalities in the Disc1-L100P mouse model for several reasons. First, valproic acid is already approved for use in teenagers as a mood stabilizer and anticonvulsant [16], [39]. 15 Second, schizophrenia is caused by multiple factors that interact at many biological levels [40], so improved treatment may have to target multiple mechanisms [41]. Valproic acid is a drug with many pharmacological actions [16], [42], [43], [44], [45] and targets, including GABA transaminase, voltage-gated sodium channels, glycogen synthase kinase (GSK)-3, and histone deacetylases (HDACs) [16]. Thus, it was used as a screen to test if early intervention in an animal model for schizophrenia is feasible. Finally, we chose not to test antipsychotic medications because clinical trials during the prodrome of schizophrenia showed limited benefit [46].

To our knowledge, this is the first report of delayed onset of schizophrenia-related behaviors in a genetic animal model of schizophrenia. However, adolescent onset of schizophrenia-related behaviors has also been observed with prenatal immune activation by polyinosinic–polycytidilic acid (poly I:C) [47], and risperidone pre-treatment can prevent brain and behavioral abnormalities if administered in adolescence [48]. The beneficial effects of valproic acid on Disc1-L100P mice are similar to its efficacy in other mouse models of schizophrenia [19], [49], [50]. Importantly, we found that chronic valproic acid treatment prevented schizophrenia-related behaviors for three weeks after the last dose. Thus, we argue that valproic acid treatment may have altered brain development, rather than just having acute effects, which represents a new paradigm for preventive treatments [51].

Genome-wide expression profiling identified large effects of the Disc1-L100P mutation in the hippocampus, an area with high DISC1 expression [52]; smaller but still significant effects were also seen in the brain stem, consistent with a wide-ranging DISC1 functional network [53]. Valproic acid alone had minimal effects on gene expression in hippocampus and striatum, consistent with the limited behavioral effect on WT animals. As expected, valproic acid affected expression of transcription factors (Egr2 and Fosb), genes involved in epigenetic regulation (Hist1h1c and Hist1h2be) and neuronal excitability (Clcn2) [16]. Valproate had broad transcriptional effects in DISC1 mutants, correcting 21.3% of altered gene expression in the hippocampus. Moreover, we detected convergent effects of both Disc1-L100P and valproate on expression of 14 genes, of which five are independently associated with schizophrenia (Tables S26).

Glial cells are important in synaptic function, maturation and elimination, and are thus a potential therapeutic target for brain disorders [54]. Here, we describe for the first time, an association of schizophrenia-related behavior in Disc1 mutant mice with increased LCN2 and GFAP+ glial cells in the SVZ. We found similar results with pharmacological inhibition (Figure 4a–d) and genetic inactivation of Lcn2 (Figure 5c–d; Table S8). LCN2 is a glycoprotein initially purified from neutrophils [55], that transports fatty acids and iron, induces apoptosis, regulates innate immunity [30], and is a pro-neoplastic factor [30]. LCN2 is secreted by astrocytes [56] and over-expression in zebrafish increased the number and activity of GFAP+ glial cells [34]. Furthermore, mild cognitive impairment is associated with higher plasma LCN2 levels [57]. One possible connection between Disc1 and Lcn2 is the Rho-ROCK pathway, through which LCN2 modifies reactive astrocytes [34]. The Disc1-L100P mutation decreased expression of three Rho-related genes (Cdc42ep2; Arhgap24 and Rock2; Table S3).

There are several limitations of the work described here. A recent study of the Disc1-L100P mice backcrossed onto the C57BL/6JJcl strain did not show the same phenotype as the original paper characterizing this mutant [11], [58]. C57BL/6JJcl was the original strain subject to ENU mutagenesis, but C57BL/6J was the strain backcrossed before phenotyping in the original report. Thus it is possible that genetic background could affect the phenotype, and that the results of the cross to the Lcn2 knock-out mice are not specific to inactivation of the Lcn2 gene. Previous studies have found that the antipsychotics haloperidol [13] and clozapine [11] corrected behavioural abnormalities in adult (week 12–16) Disc1-L100P mice, but did not assess effects on behaviour when treatment was delivered earlier, nor whether the drug effects persisted after treatment stopped, as was done in the current study. Finally, the L100P (T334C) mutation is not a polymorphism in humans associated with schizophrenia, so direct comparison across species is not possible. However, the Disc1-L100P mutation does provide general insights about the possible effects of DISC1 variants in humans.

In conclusion, the current study demonstrates that Disc1-L100P mutant mice have a developmental onset of behavioral and cellular abnormalities that parallels some clinical features of schizophrenia. We have shown that glial proliferation is increased by Disc1-L100P mutation and that early treatment with valproic acid or by genetic inactivation of Lcn2 can rectify this abnormal proliferation in conjunction with normalizing behavior. Future experiments will investigate molecular mechanisms underlying the functional association of DISC1 and LCN2 in the brain and the potential for valproic acid as a treatment in prodromal patients. LCN2 might also be useful as new biomarker for the prodromal stage of schizophrenia and as a potential new therapeutic target.

Supporting Information

Table S1

Acoustic Startle Response in Vehicle−/Valproic acid-treated Disc1-L100P and WT mice.


Table S2

List of up-regulated genes affected by Disc1-L100P mutation in the hippocampus.


Table S3

List of down-regulated genes affected by Disc1-L100P mutation in the hippocampus.


Table S4

List of genes affected by Disc1-L100P mutation in the brainstem.


Table S5

List of genes affected by valproic acid in a Disc1-independent manner.


Table S6

List of genes affected by Disc1-L100P × valproate interactions.


Table S7

Immunohistochemistry for neuron number, cell death and cell proliferation.


Table S8

Effects of genetic inactivation of Lcn2 on intensity of GFAP+ and LCN2+ cells per um2 in the brain of 12 week old Disc1-L100P mutant mice.



We thank Dr. Andrea Jurisicova for helpful discussions, Dr. John Gerogiou for his guidance with confocal microscopy, Lia Mesbah-Oskui for her help with perfusion of brains, the Centre of Modeling of Human Diseases (CMHD) for immunohistochemistry and the Advanced Optical Microscope Facility (AOMF) at Princess Margaret Hospital.

Funding Statement

The study was supported by a Canadian Institutes for Health Research (CIHR) operating grant GMH79044 and a CIHR Clinician-Scientist Fellowship to AHCW, who also holds a NARSAD Independent Investigator Award and an OMHF Mid-career Investigator Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25: 409–432. Epub 2002 Mar 2022. [PubMed]
2. Brandon NJ, Sawa A (2011) Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 12: 707–722 [PubMed]
3. Porteous DJ, Millar JK, Brandon NJ, Sawa A (2011) DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 17: 699–706 [PMC free article] [PubMed]
4. Enomoto A, Asai N, Namba T, Wang Y, Kato T, et al. (2009) Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron 63: 774–787 [PubMed]
5. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, et al. (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136: 1017–1031 [PMC free article] [PubMed]
6. Kim JY, Duan X, Liu CY, Jang MH, Guo JU, et al. (2009) DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 63: 761–773 [PMC free article] [PubMed]
7. Lee FH, Fadel MP, Preston-Maher K, Cordes SP, Clapcote SJ, et al. (2011) Disc1 point mutations in mice affect development of the cerebral cortex. J Neurosci 31: 3197–3206 [PubMed]
8. Li W, Zhou Y, Jentsch JD, Brown RA, Tian X, et al. (2007) Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A 104: 18280–18285 [PubMed]
9. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, et al. (2011) Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 16: 293–306 [PMC free article] [PubMed]
10. Papaleo F, Lipska BK, Weinberger DR (2011) Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology. [PubMed]
11. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, et al. (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54: 387–402 [PubMed]
12. Gottesman, II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636–645 [PubMed]
13. Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, et al. (2010) Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav 9: 777–789 [PubMed]
14. Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, et al. (2011) Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65: 234–248 [PubMed]
15. Brown SM, Clapcote SJ, Millar JK, Torrance HS, Anderson SM, et al. (2012) Synaptic modulators Nrxn1 and Nrxn3 are disregulated in a Disc1 mouse model of schizophrenia. Mol Psychiatry 17: 469 [PubMed]
16. Monti B, Polazzi E, Contestabile A (2009) Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2: 95–109 [PubMed]
17. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, et al. (2006) Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 103: 1834–1839 [PubMed]
18. Berger T, Cheung CC, Elia AJ, Mak TW (2010) Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci U S A 107: 2995–3000 [PubMed]
19. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, et al. (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 57: 500–509 [PubMed]
20. Semeralul MO, Boutros PC, Likhodi O, Okey AB, Van Tol HH, et al. (2006) Microarray analysis of the developing cortex. J Neurobiol 66: 1646–1658 [PubMed]
21. Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23: 2183–2184 [PubMed]
22. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG (2008) BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24: 2921–2922 [PMC free article] [PubMed]
23. Edwards D (2003) Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics 19: 825–833 [PubMed]
24. Lin SM, Du P, Huber W, Kibbe WA (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11. [PMC free article] [PubMed]
25. Boutros PC, Okey AB (2005) Unsupervised Pattern Recognition: An Introduction to the Whys and Wherefores of Clustering Microarray Data. Briefings in Bioinformatics 6: in press. [PubMed]
26. Willott JF, Tanner L, O’Steen J, Johnson KR, Bogue MA, et al. (2003) Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav Neurosci 117: 716–727 [PubMed]
27. Zheng QY, Johnson KR, Erway LC (1999) Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hear Res 130: 94–107 [PMC free article] [PubMed]
28. Zuckerman L, Rimmerman N, Weiner I (2003) Latent inhibition in 35-day-old rats is not an “adult” latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl) 169: 298–307 [PubMed]
29. Arguello PA, Gogos JA (2006) Modeling madness in mice: one piece at a time. Neuron 52: 179–196 [PubMed]
30. Rodvold JJ, Mahadevan NR, Zanetti M (2012) Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett 316: 132–138 [PubMed]
31. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132: 645–660 [PubMed]
32. Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593–624 [PubMed]
33. Schnieder TP, Dwork AJ (2011) Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 69: 134–139 [PubMed]
34. Lee S, Park JY, Lee WH, Kim H, Park HC, et al. (2009) Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci 29: 234–249 [PubMed]
35. Walker EF, Savoie T, Davis D (1994) Neuromotor precursors of schizophrenia. Schizophr Bull 20: 441–451 [PubMed]
36. Lawrie SM, McIntosh AM, Hall J, Owens DG, Johnstone EC (2008) Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 34: 330–340 [PMC free article] [PubMed]
37. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, et al. (2009) Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 35: 894–908 [PMC free article] [PubMed]
38. Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, et al. (2005) What causes the onset of psychosis? Schizophr Res 79: 23–34 [PubMed]
39. Perucca E, Tomson T (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10: 446–456 [PubMed]
40. Kirkbride JB, Jones PB (2011) The prevention of schizophrenia–what can we learn from eco-epidemiology? Schizophr Bull 37: 262–271 [PMC free article] [PubMed]
41. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, et al. (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71–93 [PMC free article] [PubMed]
42. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734–36741 [PubMed]
43. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292–295 [PubMed]
44. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, et al. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321: 892–901 [PubMed]
45. Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010. [PMC free article] [PubMed]
46. Marshall M, Rathbone J (2011) Early intervention for psychosis. Cochrane Database Syst Rev: CD004718. [PubMed]
47. Zuckerman L, Weiner I (2003) Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) 169: 308–313 [PubMed]
48. Piontkewitz Y, Arad M, Weiner I (2011) Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 37: 1257–1269 [PMC free article] [PubMed]
49. Flood DG, Choinski M, Marino MJ, Gasior M (2009) Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) 205: 369–377 [PubMed]
50. Umeda K, Suemaru K, Todo N, Egashira N, Mishima K, et al. (2006) Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice. Eur J Pharmacol 553: 157–162 [PubMed]
51. Insel TR (2010) Rethinking schizophrenia. Nature 468: 187–193 [PubMed]
52. Schurov IL, Handford EJ, Brandon NJ, Whiting PJ (2004) Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 9: 1100–1110 [PubMed]
53. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, et al. (2007) Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 12: 74–86 [PubMed]
54. Bolton MM, Eroglu C (2009) Look who is weaving the neural web: glial control of synapse formation. Curr Opin Neurobiol 19: 491–497 [PubMed]
55. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425–10432 [PubMed]
56. Delcourt N, Jouin P, Poncet J, Demey E, Mauger E, et al. (2005) Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes. Mol Cell Proteomics 4: 1085–1094 [PubMed]
57. Choi J, Lee HW, Suk K (2011) Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 305: 28–33 [PubMed]
58. Shoji H, Toyama K, Takamiya Y, Wakana S, Gondo Y, et al. (2012) Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and -L100P mutant mice. BMC Res Notes 5: 108. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science